facebook button Trials
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Current Trials

Condition Name Sponsor
Solid Tumors TAPISTRY: Multiple Cohort Solid Tumor Trial Hoffmann-La Roche
Solid Tumors STARTRK-2 Ignyta, Inc.
Observational CARIS Molecular Intelligence Registry Caris Life Sciences, Inc.
Non-Small Cell Lung Cancer TR(ACE) Assay Clinical Specimen Study Biological Dynamics
Chemotherapy-Induced Oral Mucositis Chemo Mouthpiece Medical Device Trial Chemo Mouthpiece
Non-Small Cell Lung Cancer Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer Spectrum Pharmaceuticals, Inc.
Small Cell Lung Cancer RESILIENT: Second Line Irinotecan Versus Topotecan IPSEN Bioscience, Inc.
Non-Small Cell Lung Cancer LEAP-008: Second Line Lenvatinib and Pembrolizumab Merck Sharp & Dohme Corp.
Sample Collection SeraTrials Seratrials
Sample Collection MT Group MT Group, Inc
Observational Study informCLL Registry Study for Chronic Lymphocytic Leukemia Pharmacyclics LLC.
Observational Study MOST Myelofibrosis and Essential Thrombocythemia Registry Incyte Corporation
Observational Study Palbociclib in Real World Practice Breast Cancer Registry Pfizer
Diffuse Large B-Cell Lymphoma Brentuximab Plus Lenalidomide and Rituximab Seagen
Breast Cancer DS8201a in HER2+ Patients Previously Treated with T-DM1 Daiichi Sankyo, Inc.
Prostate Cancer KPG-121 in Castration Resistant Prostate Cancer Kangpu Biopharmaceuticals, Ltd.
Triple Negative Breast Cancer CONTESSA Trio: Tesetaxel Plus Immunotherapy Odonate Therapeutics, Inc.
Advanced Solid Tumors Cabozantinib plus Atezolizumab in Multiple Tumor Types Exelixis
Prostate Cancer Ipatasertib for Patients Previously Treated with Androgen Deprivation Therapy Genentech, Inc.
Renal Cell Carcinoma NKTR-214 and Nivolumab in Previously Untreated Renal Cell Carcinoma Nektar Therapeutics
Chemotherapy Induced Anemia Roxadustat for Patients with Chemotherapy Induced Anemia FibroGen, Inc.
Solid Tumors LODESTAR: Rucaparib in HRD Mutated Solid Tumors Clovis Oncology, Inc.
Prostate Cancer PARP Inhibitor Pamiparib in HRD Mutated Protstate Cancer BeiGene, Ltd.
Prostate Cancer Docetaxel in Combination with Nivolumab or Placebo Bristol-Myers Squibb
Non-Small Cell Lung Cancer ZN-e4 for Patients with an EGFR Mutation Zeno Pharmaceuticals, Inc.
Sample Collection SEERPRO Blood Sample Collection Seer, Inc.
Oropharynx or Oral Cavity Cancer ROMAN: GC4419 for Radiation Induced Oral Mucositis Galera Therapeutics, Inc.
Urothelial Carcinoma Derzantinib for Patients with a Mutation in FGFR1-3 Basilea Pharmaceutica
Solid Tumors KEYLYNK-007: Nivolumab plus Olaparib for Patients with HRR Mutated Solid Tumors Merck Sharp & Dohme Corp.
Pancreatic Cancer Napoli: First Line Onivyde, Oxaliplatin, and 5-FU/Leucovorin Versus Gemcitabine and Nab-Paclitaxel Ipsen Bioscience
Hematologic Malignancies KPG-818 for Patients with Hematologic Malignancies Kangpu Biopharmaceuticals, Ltd.
Observational Study LocoMMotion: Multiple Myeloma Registry Janssen Scientific and Medical Affairs
Sample Collection Molecular Evaluation of NSCLC Tissue Samples Amgen Inc.
Solid Tumor or Lymphoma Anti-CD47 Antibody ZL-1201 for Patients With Advanced Solid Tumors Zai Lab Co.
Observational Study CASE: Cemiplimab in Cutaneous Squamous Cell Carcinoma Regeneron Pharmaceuticals, Inc.
Observational Study PREVAIL: Urothelial Carcinoma Registry AstraZeneca
Non-Small Cell Lung Cancer CodeBreak 200: AMG 510 for Patients with a KRAS p.G12C Mutation Amgen Inc.